EP1836313A4 - METHOD FOR ASSESSING PATIENTS WITH AKUTER MYELOIDER LEUKEMIA - Google Patents

METHOD FOR ASSESSING PATIENTS WITH AKUTER MYELOIDER LEUKEMIA

Info

Publication number
EP1836313A4
EP1836313A4 EP05854761A EP05854761A EP1836313A4 EP 1836313 A4 EP1836313 A4 EP 1836313A4 EP 05854761 A EP05854761 A EP 05854761A EP 05854761 A EP05854761 A EP 05854761A EP 1836313 A4 EP1836313 A4 EP 1836313A4
Authority
EP
European Patent Office
Prior art keywords
estimating
myeloid leukemia
patients suffering
acute myeloid
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05854761A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1836313A2 (en
Inventor
Mitch Raponi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of EP1836313A2 publication Critical patent/EP1836313A2/en
Publication of EP1836313A4 publication Critical patent/EP1836313A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP05854761A 2004-12-17 2005-12-19 METHOD FOR ASSESSING PATIENTS WITH AKUTER MYELOIDER LEUKEMIA Withdrawn EP1836313A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US67011605P 2005-04-11 2005-04-11
US74118005P 2005-12-01 2005-12-01
PCT/US2005/046100 WO2006066240A2 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia

Publications (2)

Publication Number Publication Date
EP1836313A2 EP1836313A2 (en) 2007-09-26
EP1836313A4 true EP1836313A4 (en) 2010-06-30

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05854761A Withdrawn EP1836313A4 (en) 2004-12-17 2005-12-19 METHOD FOR ASSESSING PATIENTS WITH AKUTER MYELOIDER LEUKEMIA

Country Status (9)

Country Link
EP (1) EP1836313A4 (pt)
JP (1) JP2008523822A (pt)
KR (1) KR20070099564A (pt)
AU (1) AU2005316291A1 (pt)
BR (1) BRPI0515794A (pt)
CA (1) CA2589055A1 (pt)
IL (1) IL183555A0 (pt)
MX (1) MX2007007401A (pt)
WO (1) WO2006066240A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (ko) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) 급성 골수성 백혈병 환자의 항암제 치료 반응성 예측용마커
WO2008094545A2 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
EP2272028A1 (en) * 2008-04-25 2011-01-12 Koninklijke Philips Electronics N.V. Classification of sample data
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011131246A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012007783A1 (en) * 2010-07-13 2012-01-19 Institut Gustave Roussy Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
KR101660322B1 (ko) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 ＮＰＭ1 유전자의 ｅｘｏｎ12 변이의 검출용 프로브 및 그 용도
KR101922761B1 (ko) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 급성 골수성 백혈병 진단을 위한 ｃ―Ｋｉｔ 돌연변이 실시간 정량 ＰＣＲ 분석법 및 이의 이용
CN116004819B (zh) * 2022-08-19 2025-10-31 安徽同科生物科技有限公司 AML相关的lncRNA标志物、检测试剂盒及方法在AML诊断与预后中的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Affymetrix GeneChip Human Genome U133 Array Set HG-U133A", GEO,, 11 March 2002 (2002-03-11), XP002254749 *
BULLINGER L ET AL: "USE OF GENE-EXPRESSION PROFILING TO IDENTIFY PROGNOSTIC SUBCLASSES IN ADULT ACUTE MYELOID LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US LNKD- DOI:10.1056/NEJMOA031046, vol. 350, no. 16, 15 April 2004 (2004-04-15), pages 1605 - 1616, XP009059431, ISSN: 1533-4406 *
GREENBAUM DOV ET AL: "Interrelating different types of genomic data, from proteome to secretome: 'Oming in on function", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, WOODBURY, NY, US, vol. 11, no. 9, 1 September 2001 (2001-09-01), pages 1463 - 1468, XP009088703, ISSN: 1088-9051, DOI: 10.1101/GR.207401 *
KOHLMANN A ET AL: "GENE EXPRESSION PROFILES OF DISTINCT AML SUBTYPES IN COMPARISON TO NORMAL BONE MARROW", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11, PART 01, 16 November 2001 (2001-11-16), XP001108980, ISSN: 0006-4971 *
RAPONI MITCH ET AL: "IDENTIFICATION OF MOLECULAR PREDICTORS OF RESPONSE TO ZARNESTRA (TM) (TIPIFARNIB, R115777) IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 104, no. 11, PART 1, 1 November 2004 (2004-11-01), XP009072584, ISSN: 0006-4971 *
SCHOCH CLAUDIA ET AL: "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.142103599, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 10008 - 10013, XP002215484, ISSN: 0027-8424 *
VALK P J M ET AL: "PROGNOSTICALLY USEFUL GENE-EXPRESSION PROFILES IN ACUTE/MYELOID LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US LNKD- DOI:10.1056/NEJMOA040465, vol. 350, no. 16, 15 April 2004 (2004-04-15), pages 1617 - 1628, XP009060381, ISSN: 1533-4406 *

Also Published As

Publication number Publication date
IL183555A0 (en) 2007-09-20
CA2589055A1 (en) 2006-06-22
EP1836313A2 (en) 2007-09-26
BRPI0515794A (pt) 2008-08-05
AU2005316291A1 (en) 2006-06-22
JP2008523822A (ja) 2008-07-10
MX2007007401A (es) 2007-10-08
KR20070099564A (ko) 2007-10-09
WO2006066240A8 (en) 2006-09-08
WO2006066240A2 (en) 2006-06-22
WO2006066240A3 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
FR2916839B1 (fr) Procede d'estimation de la precision d'orientations azimutales
FR2861180B1 (fr) Procede pour l'estimation des caracteristiques d'une precipitation
EP1589681A4 (en) FADING FREQUENCY ESTIMATION DEVICE
FR2917520B1 (fr) Procede d'estimation de la corrosion.
EP1905195A4 (en) DSL SYSTEM ESTIMATION
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
EP1734986A4 (en) METHOD FOR MODULATING THE APPETITE
BRPI0311233A2 (pt) diagnóstico de carcinoma hepatocelular
FR2881732B1 (fr) Procede pour la purification de chlorure d'hydrogene
EP1836313A4 (en) METHOD FOR ASSESSING PATIENTS WITH AKUTER MYELOIDER LEUKEMIA
FR2858063B1 (fr) Procede d'estimation du taux de couverture d'illumination dans le domaine migre
EP1692150A4 (en) Process for manufacture of pentaerythritol diphosphites
EP1886622A4 (en) DEVICE FOR EVALUATING ENDOSCOPE STERILIZATION
EP1740923A4 (en) HYSTERESEAUSGLEICHSYSTEM
FR2854318B1 (fr) Determination de la position d'un element anatomique
FI20030778A0 (fi) Taudin määrittäminen tai ennustaminen
EP1883351A4 (en) METHOD FOR FORECASTING A BLOOD SUGAR MIRROR OF A PERSON
EP1807987A4 (en) CHANNEL ESTIMATE
EP1743953A4 (en) Method for forming copper film
EP1624603A4 (en) CHANNEL VALUABLING AND CHANNEL VALUATION METHOD
EP1825904A4 (en) METHOD FOR ESTIMATING A STABILIZED MEMBRANE FILTER FLOW
EP1752761A4 (en) METHOD FOR MEASURING THE CONCENTRATION OF A POLLUTION ELEMENT
EP1718631A4 (en) CYTOTOXIN COMPOUND AND INSULATION METHOD
EP1825611A4 (en) CHANNEL ASSESSMENT BASED ON PILOT DIVERSITY
EP1784216A4 (en) S100 PROTEIN INHIBITOR FOR THE TREATMENT OF LEUKEMIA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070711

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107710

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20080717

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20080827BHEP

Ipc: C12P 19/34 20060101ALI20080827BHEP

Ipc: C07H 21/04 20060101ALI20080827BHEP

Ipc: C07H 21/02 20060101AFI20080827BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100602

17Q First examination report despatched

Effective date: 20110401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110812

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1107710

Country of ref document: HK